Eli Lilly And Co vs BIO-TECHNE Corp — how do they compare? Eli Lilly And Co trades at $1,220.8 (market cap $1.08T), while BIO-TECHNE Corp trades at $72.23 (market cap $11.24B). The key difference: Eli Lilly And Co is far larger — about 96.1× BIO-TECHNE Corp's market cap, and Eli Lilly And Co pays the higher dividend (0.57%). Which is the better fit depends on your goals.
| LLY | TECH | |
|---|---|---|
Market Cap | $1.08T | $11.24B |
Sector | Health | Health |
52-Week High | $1.24K | $72.29 |
52-Week Low | $639.43 | $43.31 |
Enterprise Value | $1.13T | $11.32B |
Dividend Yield | 0.57% | 0.44% |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
Bio-Techne (TECH) trades at $72.11, down 0.01% on the day, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q2 2026. The company reported Q4 2026 revenue of $321.2 million, with organic growth of 3%, and declared a $0.08 dividend. However, net income margin has declined from 25.09% in 2023 to 6.01% in 2025, and valuation ratios like P/E of 103.09 remain elevated.
The outlook is mixed: strong cash flow and institutional interest support upside, but high valuation and margin compression pose risks. Analysts are evenly split between Buy and Hold, with a consensus price target of $71.67, slightly below the current price, indicating cautious optimism amid execution challenges.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →